Rhythm Pharmaceuticals (RYTM) Amortization of Deferred Charges (2023 - 2026)

Rhythm Pharmaceuticals (RYTM) has 4 years of Amortization of Deferred Charges data on file, last reported at $4.6 million in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 15.37% year-over-year to $4.6 million in Q1 2026; TTM through Mar 2026 was $19.8 million, a 10.22% decrease from a year earlier, with the FY2025 full-year figure at $20.6 million, changed 0.09% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $4.6 million, down from $4.6 million in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for RYTM reached as high as $5.9 million in Q2 2024 and fell as low as $3.1 million in Q3 2023.
• Historically, Amortization of Deferred Charges has averaged $4.8 million across 4 years, with a median of $4.7 million in 2025.
• Across the five-year window, Amortization of Deferred Charges surged 66.52% in 2024 and declined 15.37% in 2026, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $4.0 million in 2023, then jumped by 35.56% to $5.4 million in 2024, then decreased by 15.26% to $4.6 million in 2025, then retreated by 0.84% to $4.6 million in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $4.6 million in Q1 2026, $4.6 million in Q4 2025, and $4.7 million in Q3 2025.